» Articles » PMID: 21497619

Comparative Community Outreach to Increase Cervical Cancer Screening in the Mississippi Delta

Overview
Journal Prev Med
Specialty Public Health
Date 2011 Apr 19
PMID 21497619
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of the study was to increase participation in cervical cancer screening of under-screened women living in the Mississippi Delta, a U.S. population at high risk for cervical cancer.

Methods: We conducted a door-to-door feasibility study of women living in the Mississippi Delta to increase participation in cervical cancer screening in 2009-10. Women (n=119) aged 26-65 years who had not been screened in last 3 years or more, were not pregnant, and had a cervix were offered a cost-free choice: clinic-based Pap testing or home self-collection with HPV DNA testing.

Results: Seventy-seven women (64.7%) chose self-collection with HPV testing, of which sixty-two (80.5%) returned their self-collected specimen. By comparison, 42 women (35.3%) chose Pap testing, of which 17 (40.5%) attended their clinic appointment. Thus there was an almost 4-fold greater participation of under-screened women in self-collection with HPV testing than in free Pap testing (78.4% vs. 21.5%).

Conclusions: We found that offering self-collection will increase participation in cervical cancer screening among under-screened populations living in the Mississippi Delta. Based on these preliminary results, we suggest that self-collection with HPV DNA testing might complement current Pap testing programs to reach under-screened populations of women, such as those living in the Mississippi Delta.

Citing Articles

Association Between Medicaid Expansion and Insurance Status, Risk Group, Receipt, and Refusal of Treatment Among Men with Prostate Cancer.

Patel T, Jain B, Dee E, Kohli K, Ranganathan S, Janopaul-Naylor J Cancers (Basel). 2025; 17(3).

PMID: 39941913 PMC: 11817437. DOI: 10.3390/cancers17030547.


Identifying optimum implementation for human papillomavirus self-sampling in underserved communities: A systematic review.

Mackay O, Lifford K, Kalra A, Williams D J Med Screen. 2024; 32(1):2-18.

PMID: 39212004 PMC: 11869506. DOI: 10.1177/09691413241274312.


Randomized experimental population-based study to evaluate the acceptance and completion of and preferences for cervical cancer screening.

Lordelo M, Oliveira C, Aguirre Buexm L, Reis R, Longatto-Filho A, Possati-Resende J PLoS One. 2024; 19(8):e0306130.

PMID: 39121102 PMC: 11315343. DOI: 10.1371/journal.pone.0306130.


Experiences of Self-Sampling and Future Screening Preferences in Non-Attenders Who Returned an HPV Vaginal Self-Sample in the YouScreen Study: Findings From a Cross-Sectional Questionnaire.

Drysdale H, Marlow L, Lim A, Waller J Health Expect. 2024; 27(4):e14118.

PMID: 38953514 PMC: 11217896. DOI: 10.1111/hex.14118.


Harvest for health in survivors of chronic disease: A demonstration project in the Alabama Black Belt and Mississippi Delta Region.

Bail J, Wilson J, Tipre M, Duck A, Hall K, Akinyele O Transl Behav Med. 2023; 14(2):127-137.

PMID: 37824851 PMC: 10849179. DOI: 10.1093/tbm/ibad062.


References
1.
Belinson J, Qiao Y, Pretorius R, Zhang W, Keaton K, Elson P . Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. Int J Gynecol Cancer. 2001; 9(5):411-417. DOI: 10.1046/j.1525-1438.1999.99055.x. View

2.
Wright Jr T, Denny L, Kuhn L, Pollack A, Lorincz A . HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA. 2000; 283(1):81-6. DOI: 10.1001/jama.283.1.81. View

3.
Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

4.
Garland S, Hernandez-Avila M, Wheeler C, Perez G, Harper D, Leodolter S . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-43. DOI: 10.1056/NEJMoa061760. View

5.
Castle P, Aftab A, Saint-Jean G, Mendez L . Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device. J Clin Microbiol. 2006; 44(6):2158-9. PMC: 1489444. DOI: 10.1128/JCM.02358-05. View